<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04725201</url>
  </required_header>
  <id_info>
    <org_study_id>2021-9178</org_study_id>
    <nct_id>NCT04725201</nct_id>
  </id_info>
  <brief_title>Prospective Study on the Role of Intravenous Unfractionated Heparin Following Digital Replantation and Revascularization</brief_title>
  <official_title>Prospective Study on the Role of Intravenous Unfractionated Heparin Following Digital Replantation and Revascularization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of therapeutic dose intravenous&#xD;
      heparin at improving replantation/revascularization success and its indications (if any) in&#xD;
      participants who have suffered traumatic digital amputation. Digital&#xD;
      replantation/revascularization success will be assessed in participants who receive&#xD;
      continuous intravenous drip of thromboprophylactic heparin at a therapeutic dose (i.e.&#xD;
      modifies INR to the desired range) contrasted to those who do not receive therapeutic dose&#xD;
      heparin (i.e. does not modify INR to the desired range). In the study,&#xD;
      replantation/revascularization success is defined as a clearly viable digit at the time of&#xD;
      discharge. Secondary objectives include assessing postoperative complications associated with&#xD;
      heparin use, such as bleeding, hematoma or heparin induced thrombocytopenia. The&#xD;
      investigators would also assess the impact of categorical variables such as smoking status,&#xD;
      mechanism of injury and comorbidities, on digital survival.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 24, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 24, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective randomized double-blinded clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success of digit replantation or revascularization</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Success is defined as a clearly viable digit, determined by saturation with a pulse oximeter or by bleeding on needle pinprick.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heparin-related complications</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Complications include but are not limited to bleeding at or away from site of injury, hematoma, heparin-induced thrombocytopenia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">188</enrollment>
  <condition>Amputation; Traumatic, Hand</condition>
  <arm_group>
    <arm_group_label>Intravenous unfractionated heparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of intravenous unfractionated heparin according to the Centre hospitalier de l'Université de Montréal (CHUM) deep vein thrombosis (DVT) protocol for 5 days after vascular anastomosis. A bolus will be administered intraoperatively based on the patient's weight. Dosages will be adjusted according to the activated partial thromboplastin time (aim for an APTT of 50-70), which will be measured 6 hours after the start of the protocol and after every dosage adjustment or every morning at 6 a.m. if no adjustments were made in the last 6 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>No administration of intravenous unfractionated heparin. These patients receive 5000 IU BID of heparin subcutaneously, as a standard post-operative protocol for all in-patients.&#xD;
The control group receives sham bolus intraoperatively of normal saline and a post-operative normal saline infusion at a fixed dose through an infusion pump to mimic IV heparin infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous unfractionated heparin</intervention_name>
    <description>See experimental arm description for intervention description.</description>
    <arm_group_label>Intravenous unfractionated heparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>See sham comparator arm description for intervention description.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All replantation and revascularization patients who are accepted into the CEVARMU&#xD;
             program at the Centre hospitalier de l'Université de Montréal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients on anticoagulants, other than ASA, prior to admission (i.e. Coumadin,&#xD;
             Eliquis, Pradaxa, Plavix, or similar medications)&#xD;
&#xD;
          -  Patients with a contraindication for heparin (e.g. coagulopathy, acute ulcers,&#xD;
             thrombocytopenia, severe liver damage, shock)&#xD;
&#xD;
          -  Patients who suffered an amputation in the level of the carpal tunnel and proximal to&#xD;
             it&#xD;
&#xD;
          -  Patients who experienced a degloving injury&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Mastropasqua, MD FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Montréal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linda M Zhu</last_name>
    <phone>5148908000</phone>
    <email>linda.zhu@mail.mcgill.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Zhu</last_name>
      <email>linda.zhu@mail.mcgill.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 9, 2021</study_first_submitted>
  <study_first_submitted_qc>January 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2021</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Replantation</keyword>
  <keyword>Revascularization</keyword>
  <keyword>Unfractionated heparin</keyword>
  <keyword>Finger</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amputation, Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

